viewImugene Ltd

Imugene director shows faith in company strategy with on-market share purchase

The company's lead product is HER-Vaxx, a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer.

Imugene Ltd - Imugene director supports company strategy with on-market share purchase
Walker now holds 28,187,210 shares in the company

Imugene Limited (ASX:IMU) director Charles Walker has shown his support for the company's medical technology strategy by purchasing shares on-market.

Walker purchased 354,340 shares in the company for an indirect interest on March 6 with a total value of more than £4,516.

He now holds 28,187,210 shares with 25 million of these in a direct interest and the remainder in an indirect interest.

Immuno-oncology treatments

Imugene is focused on developing immuno-oncology treatments CF33 and PD1-Vaxx in first-in-human studies as well as continued enrolment of its HER-Vaxx phase-2 study.

CF33 has been shown to efficiently shrink injected tumours and distant non-injected tumours in human triple-negative breast cancer, colon cancer, ovarian cancer xenograft models in mice without adverse effects.

The company’s PD1-Vaxx is a B-cell immunotherapy, peptide cancer vaccine designed to treat tumours such as lung cancer and will be trialled on patients in 2020.

HER-Vaxx is a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer with Phase 2 studies underway.

Quick facts: Imugene Ltd

Price: 0.035 AUD

Market: ASX
Market Cap: $154.91 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...



Imugene receives $4.13 million R&D tax incentive boost for commercial and...

Imugene Ltd (ASX:IMU) chief executive officer Leslie Chong and visiting US Professor Yuman Fong update Proactive on the progress of the company’s remarkable CF33 oncolytic virotherapy technology, which was acquired in July 2019. Professor Fong is the inventor of the technology and spoke about...

on 12/11/19

2 min read